Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: ranibizumab
DATE: 22/11/2022
MORE INFO
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
